Zwijndrecht

Researchers are evaluating IMVT-1402 in a global, randomized, double-blind, placebo-controlled Phase 2b study for adults with Graves disease GD who remain hyperthyroid despite antithyroid drug ATD treatment. The study aims to assess the efficacy, safety, and tolerability of IMVT-1402 in this population. Participants will receive one of two doses of IMVT-1402 or a placebo for 26 weeks. The study includes two experimental groups with different doses of IMVT-1402 and a placebo comparator group. Treatments are given over the same 26-week period to evaluate their effects. During the study, participants will be monitored to see if they become euthyroid and are able to stop ATD by Week 26. Researchers will measure thyroid hormone levels such as triiodothyronine T3 and free thyroxine FT4 at various time points, including Weeks 2, 4, and 26. Safety and tolerability will also be assessed throughout the trial, which is expected to complete in May 2027.

Researchers are evaluating the effect of muvalaplin in lowering cardiovascular risks among adults with elevated lipoproteina who either have atherosclerotic cardiovascular disease or are at risk of a first heart attack or stroke. This phase 3, randomized, double-blind study aims to investigate whether muvalaplin can reduce major adverse cardiovascular events compared to placebo in this high-risk population. Participants are randomly assigned to receive either muvalaplin or a placebo, both given orally. The study is designed with parallel groups and will last about 5.25 years, during which the occurrence of cardiovascular events and changes in lipoproteina levels will be closely monitored. Throughout the study, participants will undergo regular assessments including measurement of lipoproteina levels, monitoring of cardiovascular events such as heart attacks or strokes, and evaluation of healthcare resource use. The primary outcome is the time to first major adverse cardiac event, tracked from baseline until the study ends. Safety and pharmacokinetics of muvalaplin will also be evaluated during the trial period.

This research aims to evaluate the effectiveness of closed-loop spinal cord stimulation CL-SCS therapy in patients suffering from painful chemotherapy induced peripheral neuropathy CIPN. CIPN affects up to 40% of chemotherapy patients and causes significant pain. Traditional treatments include medications and other interventions, but evidence for their success is limited. CL-SCS is an advanced method that stimulates nerves in the spinal cord and adjusts stimulation automatically in real time to manage pain. The study involves patients diagnosed with painful CIPN who are scheduled for CL-SCS implantation using the Evoke SCS System. This system sends electrical pulses to the spinal cord, measures nerve responses, and adapts stimulation accordingly. The research observes patients receiving this treatment without a comparison group, tracking effects over time. Participants will be followed for up to 12 months after implantation. Researchers will assess changes in overall pain intensity, pain in arms or legs, CIPN symptoms, medication use, quality of life, and patient satisfaction at 1, 3, 6, and 12 months. Safety will be monitored by recording any serious adverse events during this period. The study collects detailed patient reports and device data to understand CL-SCS therapys impact on pain and quality of life in CIPN patients.